Related Experiment Video
Updated: Jun 11, 2026

A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos
Published on: November 8, 2014
Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish
Hanbing Zhong1, Shengchang Xin, Yanqiu Zhao
1Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School of Peking University, Shenzhen University Town, Shenzhen, China.
Abstract:
During the preclinical drug discovery process it remains a challenge to enable early elimination of candidate molecules that may have non-specific, off-target activities. Here, we use whole zebrafish embryo assays coupled with genetic analysis to address this issue. PLK1 (Polo-like kinase 1) is one of the key regulators that control mitotic entry, spindle assembly, chromosome segregation, and cytokinesis in the cell cycle. Since plk1 expression is abnormally up-regulated in several tumors, it is regarded as a good target for cancer therapy. A number of small-molecule inhibitors targeting PLK1 have been developed as reagents and anticancer drug candidates. It will be interesting to determine if these inhibitors indeed specifically target PLK1 in vivo. Bioinformatics analysis revealed that the zebrafish and human genomes share high homology across all PLK family members. In particular, PLK1 has a nearly identical 3-D structure between zebrafish and human. We selected three published PLK1 inhibitors, LFM-A13, ON01910, and thiazole-carboxamide 10A in our assay. When added at 2-cell stage, all of these inhibitors prevented embryos from dividing and caused cells to fuse into one large cell. When added at the later stage during zygotic mRNA transcription program initiation, embryos survived for 3 days but showed different phenotypes for each compound. Embryos treated with LFM-A13 appeared relatively normal. Embryos treated with ON01910 failed to properly develop trunk and tail regions while the head structure was unaffected. Embryos treated with thiazole-carboxamide 10A had a shorter body axis and deformed head structure. To determine which inhibitor is more selectively targeting PLK1, we inhibited PLK1 activity using anti-sense morpholino. Comparative analysis indicated that thiazole-carboxamide 10A could faithfully phenocopy zebrafish embryos genetically deficient of plk1. These findings demonstrate that these three PLK1 inhibitors, although well established by in vitro studies, have different off-target activities in vivo, and that thiazole-carboxamide 10A appears most specific to PLK1. Our studies suggest that zebrafish should be generally useful as an efficient in vivo model to evaluate specificity of small molecules designed to regulate any conserved target proteins through comparative analysis of genetic phenotypes.
Insights
Evaluating Polo-like kinase 1 (PLK1) inhibitors in zebrafish revealed significant off-target activities for LFM-A13 and ON01910. Thiazole-carboxamide 10A demonstrated the highest specificity for PLK1 in vivo, making zebrafish a valuable model for drug specificity assessment.
Area of Science:
- Pharmacology and Toxicology
- Developmental Biology
- Genetics and Genomics
Background:
- Identifying specific drug candidates early in preclinical discovery is crucial to avoid off-target effects.
- Polo-like kinase 1 (PLK1) is a key cell cycle regulator and a promising cancer therapy target.
- Developing specific PLK1 inhibitors requires robust in vivo validation due to potential off-target activities.
Purpose of the Study:
- To evaluate the in vivo specificity of three PLK1 inhibitors (LFM-A13, ON01910, thiazole-carboxamide 10A).
- To assess the utility of zebrafish whole embryo assays for determining small molecule inhibitor specificity.
- To compare the in vivo phenotypes of PLK1 inhibition with genetic deficiency of PLK1 in zebrafish.
Main Methods:
- Whole zebrafish embryo assays were employed to assess drug phenotypes.
- Three PLK1 inhibitors were administered at different developmental stages.
- Genetic analysis using anti-sense morpholino against PLK1 was performed for comparative phenotyping.
Main Results:
- All tested inhibitors caused cell fusion and division arrest at the 2-cell stage.
- At later stages, LFM-A13 showed minimal effects, ON01910 caused trunk-tail defects, and thiazole-carboxamide 10A induced body axis shortening and head deformities.
- Thiazole-carboxamide 10A phenotypically mimicked zebrafish embryos with genetic PLK1 deficiency, indicating higher specificity.
Conclusions:
- Established in vitro PLK1 inhibitors exhibit distinct off-target activities in vivo.
- Thiazole-carboxamide 10A demonstrates the most specific targeting of PLK1 in vivo among the tested compounds.
- Zebrafish embryos provide an efficient in vivo model for evaluating the specificity of small molecules targeting conserved proteins.

